Go Pro
OTCMKTS:OTSKF

Otsuka (OTSKF) Stock Price, News & Analysis

Otsuka logo
$76.10 0.00 (0.00%)
As of 09/4/2026

About Otsuka Stock (OTCMKTS:OTSKF)

Advanced

Key Stats

Today's Range
$76.10
$76.10
50-Day Range
$66.00
$77.53
52-Week Range
$54.26
$79.00
Volume
N/A
Average Volume
313 shs
Market Capitalization
N/A
P/E Ratio
0.25
Dividend Yield
73.30%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Otsuka Holdings Co., Ltd., trading on OTC markets as OTSKF, is a global healthcare company headquartered in Tokyo, Japan. Established in 1964 as a research-driven pharmaceutical firm, Otsuka has since evolved into a diversified holding company overseeing operations in pharmaceuticals, nutraceuticals and consumer products. The company operates through a network of subsidiaries, including Otsuka Pharmaceutical Co., Ltd., Otsuka America Pharmaceutical, Inc., and Otsuka Europe, each focusing on drug development, manufacturing and distribution.

In its pharmaceutical division, Otsuka is best known for discovering and commercializing treatments in areas such as psychiatry, oncology and nephrology. Flagship products include aripiprazole (marketed jointly with global partners for psychiatric disorders) and tolvaptan, a therapy for hyponatremia and polycystic kidney disease. The nutraceutical segment leverages Otsuka’s research capabilities to develop functional foods and beverages, with brands such as SoyJoy nutrition bars and Pocari Sweat, an electrolyte beverage popular in Asia.

Otsuka maintains a strong global presence, conducting research, clinical trials and manufacturing across Asia, North America, Europe and emerging markets. The company’s international network includes research centers in Japan and the United States, as well as regional marketing and distribution offices in Europe, China, India and Latin America. This broad footprint supports Otsuka’s commitment to meeting diverse healthcare needs and bringing innovative therapies to patients worldwide.

Research and development remain central to Otsuka’s strategy, with investments in novel drug delivery systems, digital therapeutics and next-generation small molecules. Collaborations with academic institutions, biotechnology firms and public health organizations further bolster the company’s pipeline. Guided by a board of directors based in Tokyo, Otsuka continues to pursue sustainable growth through scientific innovation, strategic partnerships and a focus on patient-centric solutions.

AI Generated. May Contain Errors.

Otsuka Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
7th Percentile Overall Score

OTSKF MarketRank™: 

Otsuka scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Otsuka.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Otsuka is 0.25, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 45.02.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Otsuka is 0.25, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.10.

  • Read more about Otsuka's valuation and earnings.
  • Percentage of Shares Shorted

  • Short Interest Ratio / Days to Cover

    Otsuka has a short interest ratio ("days to cover") of 999.99, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Otsuka has recently increased by 33.95%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Otsuka pays a meaningful dividend of 3.45%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Otsuka does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Otsuka is 18.48%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Read more about Otsuka's dividend.
  • News Sentiment

    Otsuka has a news sentiment score of -0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Otsuka this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Otsuka insiders have not sold or bought any company stock.

  • Percentage Held by Institutions

    12.20% of the stock of Otsuka is held by institutions.

  • Read more about Otsuka's insider trading history.
Receive OTSKF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Otsuka and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

OTSKF Stock News Headlines

Jefferies Reaffirms Their Buy Rating on Otsuka (OSUKF)
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the largest mineral reserve in the country - enough gold for a new Fort Knox, enough copper to rebuild the U.S. electric grid 25 times over. The Trump administration has previously staked positions in MP Materials, Lithium America, Trilogy Metals, and USA Rare Earth - each time shares moved higher. A landmark policy decision expected before November 3 could reprice this stock from $2 to $20 or more within a year.tc pixel
Recor Medical Names Dr. Helen Reeve-Stoffer Chief Executive Officer
See More Headlines

OTSKF Stock Analysis - Frequently Asked Questions

Otsuka's stock was trading at $54.26 on January 1st, 2026. Since then, OTSKF shares have increased by 40.3% and is now trading at $76.10.

Shares of OTSKF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Today
9/06/2026
Next Earnings (Estimated)
11/04/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
OTCMKTS:OTSKF
CIK
1544613
Fax
N/A
Employees
34,388
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
0.25
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

This page (OTCMKTS:OTSKF) was last updated on 9/6/2026 by MarketBeat.com Staff.
From Our Partners